Payment overview · 2025
General Payments
$3,388.11
151 reported records · 33 companies
Healthcare provider profile · identity verified
Robert Joseph Healy, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FLORENCE, SC · NPI 1164400123
Verified facts
What the public records show
CMS Open Payments records show Robert Joseph Healy, MD received $3,388.11 in general payments during 2025 across 151 reported records.
UCB, Inc. accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Fintepla, Fycompa, Nuplazid, Nurtec Odt, Vumerity.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuplazid by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vumerity by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FYCOMPA as an associated drug or biological on 3130 records involving 1101 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Fycompa by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ampyra by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Xcopri by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Briviact by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fintepla as an associated drug or biological on 12923 records involving 3741 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Fintepla by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $573.33 | 16.9% | 26 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $248.29 | 7.3% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $232.25 | 6.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $209.31 | 6.2% | 10 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $196.17 | 5.8% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $128.13 | 3.8% | 6 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $120.93 | 3.6% | 6 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$119.02 | 3.5% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $112.57 | 3.3% | 4 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $102.09 | 3.0% | 4 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $98.11 | 2.9% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $93.43 | 2.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $93.01 | 2.8% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $89.97 | 2.7% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $88.40 | 2.6% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $86.79 | 2.6% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $84.17 | 2.5% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.60 | 2.2% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.53 | 2.0% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $66.00 | 1.9% | 3 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.55 | 1.9% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $60.60 | 1.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.42 | 1.5% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $51.32 | 1.5% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $51.22 | 1.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $43.59 | 1.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.15 | 1.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.09 | 0.9% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $26.13 | 0.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $22.75 | 0.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.95 | 0.7% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $21.14 | 0.6% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $19.10 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,388.11 | 151 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $232.25 | 9 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $192.65 | 8 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $167.79 | 7 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $145.21 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $145.21 | 6 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $137.51 | 8 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $128.13 | 6 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $127.98 | 7 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $124.66 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $120.93 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $120.93 | 6 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $112.57 | 4 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $108.74 | 5 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $106.59 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $102.09 | 4 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $98.11 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $93.43 | 4 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $89.97 | 4 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $84.91 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $84.17 | 4 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $75.60 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $73.86 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $64.10 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $64.10 | 4 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $62.55 | 4 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $60.60 | 4 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $51.22 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $48.25 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.19 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $19.10 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Fintepla fintepla |
2025 | Fintepla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FYCOMPA fycompa |
2025 | Fycompa | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FYCOMPA open payments reported associated product |
CMS Open Payments — General Payments 3130 supporting records · 1101 recipient NPIs · example record 1253216846 |
Fycompa · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Fintepla open payments reported associated product |
CMS Open Payments — General Payments 12923 supporting records · 3741 recipient NPIs · example record 1224348643 |
Fintepla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levetiracetam | Levetiracetam | 306 | 57 |
| Lacosamide | Lacosamide | 204 | 27 |
| Pregabalin | Pregabalin | 186 | 47 |
| Donepezil Hcl | Donepezil Hcl | 164 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 143 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 142 | 35 |
| Carbamazepine Er | Carbamazepine | 118 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 28 |
| Clonazepam | Clonazepam | 102 | 19 |
| Gabapentin | Gabapentin | 97 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 95 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 26 |
| Lamotrigine | Lamotrigine | 93 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 93 | 19 |
| Amantadine | Amantadine Hcl | 89 | 16 |
| Atenolol | Atenolol | 80 | 19 |
| Sertraline Hcl | Sertraline Hcl | 78 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 77 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 75 | 16 |
| Lorazepam | Lorazepam | 64 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | 12 |
| Fycompa | Perampanel | 55 | suppressed |
| Temazepam | Temazepam | 54 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 53 | 17 |
| Aripiprazole | Aripiprazole | 52 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 51 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 51 | suppressed |
| Metformin Hcl | Metformin Hcl | 49 | suppressed |
| Carbamazepine | Carbamazepine | 48 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 47 | 11 |
| Teriflunomide | Teriflunomide | 47 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 45 | suppressed |
| Losartan Potassium | Losartan Potassium | 41 | 12 |
| Baclofen | Baclofen | 40 | suppressed |
| Xcopri | Cenobamate | 40 | suppressed |
| Vimpat | Lacosamide | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 38 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 36 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 36 | suppressed |
| Risperidone | Risperidone | 36 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 12 |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Azathioprine | Azathioprine | 31 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 27 | suppressed |
| Topiramate | Topiramate | 27 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Lactated Ringers | Ringer's Solution,lactated | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Briviact | Brivaracetam | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Lisinopril | Lisinopril | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Valtoco | Diazepam | 21 | suppressed |
| Omeprazole | Omeprazole | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Phenytoin | Phenytoin | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ampyra | Dalfampridine | 15 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Fintepla | Fenfluramine Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Vumerity | Diroximel Fumarate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carvedilol | Carvedilol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Aubagio | Teriflunomide | 11 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 11 | suppressed |
| Fingolimod | Fingolimod Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
| Trokendi Xr | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,388.11 · 151 records | UCB, Inc. | ACTHAR, AMVUTTRA, AUSTEDO XR, BRIUMVI, Briviact, EPIDIOLEX, FYCOMPA, Fintepla, Gocovri, HYQVIA, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONPATTRO, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, Qelbree, REXULTI, Rystiggo, SPRAVATO, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYVGART, VYVGART HYTRULO, Xeomin, ZAVZPRET, ZEPBOUND, ZEPOSIA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error